Cytokine Signalling Forum

Prof Iain McInnes discusses bone metabolism and PRO Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Paul Emery, an arthritis Research UK Professor of Rheumatology, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Paul discusses how baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis

Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.

Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA

Professor Tsutomu Takeuchi, HVice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA

Professor René Westhovens, Emeritus Prof of Rheumatology at the KU Leuven Belgium and a >30 year track in clinical research in Rheumatoid Arthritis. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.

Prof Iain McInnes discusses papers on filgotinib and the involvement of pain in RA. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace C Wright discusses her careeer and the future of AWIR. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world-leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Professor György Nagy from the Semmelweis University, Hungry. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA

Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.

Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA

Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.

Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib

Prof Iain McInnes discusses JAK inhibitors. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Past President of EULAR and Carol Nachman Prize winner. In this podcast, Professor Paul Emery discusses his work in managing early RA and the growth of his unit at Leeds into a world leading centre for rheumatology research alongside Professor Michael Weinblatt. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes a preview of an upcoming Highlights from ACR 2020 course from Professors Kevin Winthrop and Leonard Calabrese, available soon on the CSF website.

Prof Stanley Cohen - University of Texas. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Stanley Cohen discusses safety profile of upadacitinib